

Online supplementary materials

The effect of bicyclol on blood biomarkers of NAFLD: a systematic review and meta-analysis

Hu Li ^{1,2}, Nan-Nan Liu ¹, Zong-Gen Peng ^{1,3,*}

¹ CAMS Key Laboratory of Antiviral Drug Research, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.

² Key Laboratory of Biotechnology of Antibiotics, The National Health and Family Planning Commission (NHFP), Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.

³ Beijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.

* Correspondence should be addressed to Zong-Gen Peng (pumcpzg@126.com)

Online supplementary materials

Methods: Search Strategy

Figure S1: Funnel plot of alanine aminotransferase (A), aspartate transaminase (B), total bilirubin(C), triglyceride (D) and total cholesterol (E).

Tbale S1: Support table for risk of bias judgement

Online supplementary Methods: Search Strategy

Pubmed

| No. | Query |
|-----|--|
| 1 | Non alcoholic Fatty Liver Disease |
| 2 | NAFLD |
| 3 | nonalcoholic fatty liver |
| 4 | non-alcoholic fatty liver |
| 5 | Nonalcoholic Steatohepatitis |
| 6 | Nonalcoholic Steatohepatitides |
| 7 | 1 or 2 or 3 or 4 or 5 or 6 |
| 8 | bicyclol |
| 9 | 4,4'-bi-(1,3-benzodioxole)-5-carboxylic acid, 5'-(hydroxymethyl)-7,7'-dimethoxy-, methyl ester |
| 10 | 6-methoxycarbonyl-6'-hydroxymethyl-2,3,2',3'-bis(methylenedioxy)-4,4'- dimethoxybiphenyl |
| 11 | 8 or 9 or 10 |
| 12 | 10 and 11 |

Embase

| No. | Query |
|-----|---|
| #1 | non AND alcoholic AND fatty AND liver AND disease |
| #2 | nafld |
| #3 | nonalcoholic AND fatty AND liver |
| #4 | 'non alcoholic' AND fatty AND liver |
| #5 | nonalcoholic AND steatohepatitis |
| #6 | nonalcoholic AND steatohepatitides |
| #7 | #1 or #2 or #3 or #4 or #5 or #6 |
| #8 | bicyclol |
| #9 | #7 AND #8 |

Cochrane Library

| ID | Search |
|----|--|
| #1 | MeSH descriptor: [Non-alcoholic Fatty Liver Disease] explode all trees |
| #2 | ((nonalcoholic or non-alcoholic) near (fatty liver or steatohepatitis)):ti,ab,kw or fatty liver or steatohepatitis:ti or nafld or nash:ti,ab,kw (Word variations have been searched) |
| #3 | #1 or #2 |
| #4 | bicyclol:ti,ab,kw (Word variations have been searched) |
| #5 | #3 and #4 |

China National Knowledge Infrastructure database (CNKI)

(((主题=非酒精性脂肪性肝病 或者 题名=非酒精性脂肪性肝病 或者 v_subject=中英文扩展(非酒精性脂肪性肝病) 或者 title=中英文扩展(非酒精性脂肪性肝病)) 或者 (主题=非酒精性脂肪性肝炎 或者 题名=非酒精性脂肪性肝炎 或者 v_subject=中英文扩展(非酒精性脂肪性肝炎) 或者 title=中英文扩展(非酒精性脂肪性肝炎))) 并且 (主题=双环醇 或者 题名=双环醇 或者 v_subject=中英文扩展(双环醇) 或者 title=中英文扩展(双环醇))) (模糊匹配), 专辑导航: 全部; 数据库: 文献 跨库检索

VIP-Chinese scientific and technological journal database

((题名或关键词=非酒精性脂肪性肝病 OR 题名或关键词=非酒精性脂肪性肝炎) AND 题名或关键词=双环醇)

Wanfang digital periodical full-text database

主题词扩展&中英文扩展: (主题:(非酒精性脂肪性肝病)+主题:(非酒精性脂肪性肝炎))* *主题:(双环醇)

Figure S1. Funnel plot of alanine aminotransferase (A), aspartate transaminase (B), total bilirubin(C), triglyceride (D) and total cholesterol (E).




Table S1. Support table for risk of bias judgement

| Unique ID Study | Randomization process # | | | Deviations from intended interventions | | | | | | | Missing outcome data | | | | Measurement of the outcome | | | | | Selection of the reported result | | | Overall Bias * |
|--------------------|-------------------------|-----|-----|--|-----|-----|-----|-----|-----|-----|----------------------|-----|-----|-----|----------------------------|-----|-----|-----|-----|----------------------------------|-----|-----|----------------|
| | 1.1 | 1.2 | 1.3 | 2.1 | 2.2 | 2.3 | 2.4 | 2.5 | 2.6 | 2.7 | 3.1 | 3.2 | 3.3 | 3.4 | 4.1 | 4.2 | 4.3 | 4.4 | 4.5 | 5.1 | 5.2 | 5.3 | |
| Ding 2009 | Y | NI | Y | NI | NI | Y | N | NA | Y | NA | Y | NA | NA | NA | N | N | NI | N | NA | Y | N | N | High |
| Gao 2011 | Y | NI | Y | NI | NI | Y | N | NA | Y | NA | Y | NA | NA | NA | N | N | NI | N | NA | Y | N | N | High |
| Guan 2013 | Y | NI | Y | NI | NI | Y | N | NA | Y | NA | Y | NA | NA | NA | N | N | NI | N | NA | Y | N | N | High |
| He 2011 | Y | NI | Y | NI | NI | Y | N | NA | Y | NA | Y | NA | NA | NA | N | N | NI | N | NA | Y | N | N | High |
| Li 2014 | Y | NI | Y | NI | NI | Y | N | NA | Y | NA | Y | NA | NA | NA | N | N | NI | N | NA | Y | N | N | High |
| Liang 2007 | Y | NI | Y | NI | NI | Y | N | NA | Y | NA | Y | NA | NA | NA | N | N | NI | N | NA | Y | N | N | High |
| Liao 2011 | Y | NI | Y | NI | NI | Y | N | NA | Y | NA | Y | NA | NA | NA | N | N | NI | N | NA | Y | N | N | High |
| Sun 2015 | Y | NI | Y | NI | NI | Y | N | NA | Y | NA | Y | NA | NA | NA | N | N | NI | N | NA | Y | N | N | High |
| Yan 2017 | Y | NI | Y | NI | NI | Y | N | NA | Y | NA | Y | NA | NA | NA | N | N | NI | N | NA | Y | N | N | High |
| Zhang 2011 | Y | NI | Y | NI | NI | Y | N | NA | Y | NA | Y | NA | NA | NA | N | N | NI | N | NA | Y | N | N | High |
| Zhang 2012 | Y | NI | Y | NI | NI | Y | N | NA | Y | NA | Y | NA | NA | NA | N | N | NI | N | NA | Y | N | N | High |
| Zhu 2005 | Y | NI | Y | NI | NI | Y | N | NA | Y | NA | Y | NA | NA | NA | N | N | NI | N | NA | Y | N | N | High |

comments of Randomization process: study "Liao 2011": Random number table method, no information about allocation concealment; others: Random number table method, no information about allocation concealment

* Y/PY/PN/N/NI means Yes/Probably yes/Probably no/No/No information; Overall judgement for the result will be 'High' if one of the domains is judged at 'High' risk of bias.

1.1 Was the allocation sequence random?

1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?

1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?

2.1 Were participants aware of their assigned intervention during the trial?

2.2 Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?

2.3 If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?

2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?

2.5 Was an appropriate analysis used to estimate the effect of assignment to intervention?

3.1 Were data for this outcome available for all, or nearly all, participants randomized?

4.1 Was the method of measuring the outcome inappropriate?

4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?

4.3 If N/PN/NI to 4.1 and 4.2: Were outcome assessors aware of the intervention received by study participants?

4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?

5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?

5.2 Is the numerical result being assessed likely to have been selected, on the basis of the results, from multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?

5.3 ... multiple eligible analyses of the data?